Professor of Medicine, Paracelsus Medical University Salzburg
Verified email at
Cited by
Cited by
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised …
B Burtness, KJ Harrington, R Greil, D Souličres, M Tahara, G de Castro, ...
The Lancet 394 (10212), 1915-1928, 2019
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
J Bennouna, J Sastre, D Arnold, P Österlund, R Greil, E Van Cutsem, ...
The lancet oncology 14 (1), 29-37, 2013
Endocrine therapy plus zoledronic acid in premenopausal breast cancer
M Gnant, B Mlineritsch, W Schippinger, G Luschin-Ebengreuth, ...
New England Journal of Medicine 360 (7), 679-691, 2009
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 …
R Jakesz, W Jonat, M Gnant, M Mittlboeck, R Greil, C Tausch, J Hilfrich, ...
The Lancet 366 (9484), 455-462, 2005
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ...
New England Journal of Medicine 382 (7), 597-609, 2020
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma
A Engert, A Plütschow, HT Eich, A Lohri, B Dörken, P Borchmann, ...
New England Journal of Medicine 363 (7), 640-652, 2010
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast cancer
J Baselga, V Semiglazov, P van Dam, A Manikhas, M Bellet, ...
Journal of Clinical Oncology 27 (16), 2630-2637, 2009
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors
M Filipits, M Rudas, R Jakesz, P Dubsky, F Fitzal, CF Singer, O Dietze, ...
Clinical Cancer Research 17 (18), 6012-6020, 2011
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 …
DV Engert A, Haverkamp H, Kobe C, Markova J, Renner C, GHS Group, ...
LANCET 329 (9828), 1791-9, 2012
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer
NU Lin, V Diéras, D Paul, D Lossignol, C Christodoulou, HJ Stemmler, ...
Clinical cancer research 15 (4), 1452-1459, 2009
Monoclonal gammopathy of undetermined significance: natural history in 241 cases
RA Kyle
The American journal of medicine 64 (5), 814-826, 1978
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label …
C Moreno, R Greil, F Demirkan, A Tedeschi, B Anz, L Larratt, M Simkovic, ...
The Lancet Oncology 20 (1), 43-56, 2019
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3
E Van Cutsem, R Labianca, G Bodoky, C Barone, E Aranda, B Nordlinger, ...
Journal of Clinical Oncology 27 (19), 3117-3125, 2009
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
M Gnant, B Mlineritsch, H Stoeger, G Luschin-Ebengreuth, D Heck, ...
The lancet oncology 12 (7), 631-641, 2011
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
M Gnant, G Pfeiler, PC Dubsky, M Hubalek, R Greil, R Jakesz, V Wette, ...
The Lancet 386 (9992), 433-443, 2015
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group …
HT Eich, V Diehl, H Görgen, T Pabst, J Markova, J Debus, A Ho, B Dörken, ...
Journal of Clinical Oncology 28 (27), 4199-4206, 2010
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal …
M Gnant, M Filipits, R Greil, H Stoeger, M Rudas, Z Bago-Horvath, ...
Annals of oncology 25 (2), 339-345, 2014
Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
H Tilly, F Morschhauser, LH Sehn, JW Friedberg, M Trněný, JP Sharman, ...
New England Journal of Medicine 386 (4), 351-363, 2022
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
M Gnant, B Mlineritsch, G Luschin-Ebengreuth, F Kainberger, ...
The lancet oncology 9 (9), 840-849, 2008
Randomized phase II study of the anti–epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple …
J Baselga, P Gómez, R Greil, S Braga, MA Climent, AM Wardley, ...
Journal of clinical oncology 31 (20), 2586-2592, 2013
The system can't perform the operation now. Try again later.
Articles 1–20